[Disc: held IRL]

Graham Witcomb's recent write up on CUV over at Intelligent Investor is worth a read for those with an account (free to create). Of particular note is Graham's commentary on emerging drug "dersimelagon" which is in phase III trials and which "... works in a similar way to Scenesse but – critically – is administered as a convenient once-a-day oral tablet."

I haven't yet had a chance to do any significant digging of my own so no further insights to add at this stage, but definitely something to be aware of and keep an eye on.